mRNA |
fulvestrant |
CTRPv2 |
pan-cancer |
AAC |
0.32 |
3e-05 |
mRNA |
ISOX:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.12 |
0.0003 |
mRNA |
NVP-BEZ235 |
GDSC1000 |
pan-cancer |
AAC |
0.13 |
0.0006 |
mRNA |
Panobinostat |
CTRPv2 |
pan-cancer |
AAC |
-0.11 |
0.0008 |
mRNA |
dabrafenib |
CTRPv2 |
pan-cancer |
AAC |
0.16 |
0.0009 |
mRNA |
doxorubicin:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.11 |
0.0009 |
mRNA |
navitoclax:pluripotin (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.11 |
0.003 |
mRNA |
Doxorubicin |
gCSI |
pan-cancer |
AAC |
0.15 |
0.003 |
mRNA |
Bortezomib |
CTRPv2 |
pan-cancer |
AAC |
-0.1 |
0.004 |
mRNA |
neratinib |
CTRPv2 |
pan-cancer |
AAC |
-0.1 |
0.005 |